EUVIMEDEUVIMED entdecken
Leserbrief

How to Choose a Treatment for Immune Checkpoint Inhibitor-associated Colitis: Biologics, or Fecal Microbial Transplantation

He-Ran Wang iD, Meng-Yao Wang, Li-Xuan Sang iD

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izad071 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von He-Ran Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Provin…. Hauptthemen laut MEDLINE: Biological Products, Colitis, Antineoplastic Agents, Immunological. Die Arbeit nennt 4 Literaturangaben. Gefördert von: Shenyang Science and Technology Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editors, In recent years, immune checkpoint inhibitors (ICIs) have been used in an increasing number of oncology patients. Patients may experience treatment-related toxic reactions after the application of such drugs. We focus on immune-related adverse events (irAEs) caused by ICIs, of which ICI-associated colitis (ICIAC) is one of the most common toxic reactions in ICIs therapy. Immune checkpoint inhibitor–associated colitis is usually treated with steroid hormones of choice, and severe cases require combined immunosuppressive therapy. Here, we will discuss this type of colitis in terms of treatment. The management of ICIAC is based on the principles of timely and effective symptom control and reduction of recurrence and complications, thus achieving the maximum benefit of antineoplastic therapy. First, treatment is preferred to steroids, which are effective in most patients. The recommended first-line treatment for grade 3/4 immune-associated small bowel colitis (irEC) is high-dose glucocorticoids, but some patients with colitis become steroid-refractory.1Second, immunosuppressive therapy is used, often with infliximab (IFX) or vedolizumab. Abu-Sbeih et al suggested for irEC, early introduction of IFX therapy can reduce hormone dependence and lower the risk of irEC relapse compared with the risk of waiting for steroid hormone therapy to fail before using IFX.2 Third, fecal microbial transplantation (FMT) improves the intestinal flora of patients by extracting flora from donor stool samples and transferring them to patients. Fecal microbial transplantation is also increasingly used; Wang et al reported 2 cases of refractory-associated colitis patients who were successfully treated with FMT.3 In the first study, both patients showed complete clinical remission after treatment with FMT; and the other study reported the successful use of FMT to treat a patient with severe ICI-induced colitis who did not respond to steroid and infliximab treatment.4 Although this study showed to some extent that FMT was effective in patients who did not respond with infliximab, more evidence-based medical data is needed for the safety and long-term efficacy of FMT. In the future, we can combine with macrogenomic technology to detect the composition of intestinal flora and promote the application and development of fecal transplantation technology. The irAE management guidelines state that oral antidiarrheal medication is to be given to relieve symptoms in mild ICIAC1 and that most patients can safely continue ICIs without discontinuing the medication. As a next step, we should clarify the treatment cycle of biologics for ICIAC patients and whether they can be administered according to the treatment cycle of inflammatory bowel disease patients. Authors would like to thank the department of Gastroenterology of Shengjing Hospital of China Medical University for technical assistance. H.R.W. and M.Y.W. wrote the letter; L.X.S. supervised the manuscript drafting; each author contributed important intellectual content during manuscript drafting and revision. All authors have read and approve the final manuscript. The manuscript was funded by the Shenyang Science and Technology Plan Fund Project (No. 20-205-4-094). The project was supported by the 345 Talent Project of Shengjing Hospital The authors declare that they have no competing interests.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsColitisAntineoplastic Agents, ImmunologicalHumansImmune Checkpoint InhibitorsFecal Microbiota Transplantation

Substanzen

Immune Checkpoint InhibitorsBiological ProductsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China.

ORCID-Profile: He-Ran Wang, Li-Xuan Sang

Förderung

  • Shenyang Science and Technology Plan

Zitieren

APA

Wang, H. R., Wang, M. Y., & Sang, L. X. (2023). How to Choose a Treatment for Immune Checkpoint Inhibitor-associated Colitis: Biologics, or Fecal Microbial Transplantation. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad071

Vancouver

Wang HR, Wang MY, Sang LX. How to Choose a Treatment for Immune Checkpoint Inhibitor-associated Colitis: Biologics, or Fecal Microbial Transplantation. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izad071

BibTeX
@article{Wang2023,
  author = {Wang, He-Ran and Wang, Meng-Yao and Sang, Li-Xuan},
  title = {How to Choose a Treatment for Immune Checkpoint Inhibitor-associated Colitis: Biologics, or Fecal Microbial Transplantation},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izad071}
}
Kostenlos starten →